Efficacy of mesenchymal stem cell transplantation on major adverse cardiovascular events and cardiac function indices in patients with chronic heart failure: a meta-analysis of randomized controlled trials.
Cardiomyopathy
Heart failure
Mesenchymal stem cells
Meta-analysis
Randomized controlled trials
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
received:
11
02
2024
accepted:
29
05
2024
medline:
23
8
2024
pubmed:
23
8
2024
entrez:
22
8
2024
Statut:
epublish
Résumé
The effects of mesenchymal stem cells (MSCs) on heart failure (HF) have been controversial. This study was conducted to investigate whether the transplantation of MSCs after HF could help improve clinical outcomes and myocardial performance indices. Using a systematic approach, electronic databases were searched for randomized controlled trials (RCTs), which evaluated the transplantation of MSCs after HF. The outcomes owf interest included clinical outcomes and myocardial function indices. We also assessed the role of age, cause of heart failure, cell origin, cell number, type of donor (autologous/allogeneic), and route of cell delivery on these outcomes. Using the random-effects method, a relative risk (RR) or mean difference (MD) and their corresponding 95% confidence intervals (CI) were pooled. Seventeen RCTs including 1684 patients (927 and 757 patients in the intervention and control arms, respectively) were enrolled. The RR (95% CI) of mortality was 0.78 (0.62; 0.99, p = 0.04) in the MSC group compared to the controls. HF rehospitalization decreased in the MSC group (RR = 0.85 (0.71-1.01), p = 0.06), but this was only significant in those who received autologous MSCs (RR = 0.67 (0.49; 0.90), p = 0.008). LVEF was significantly increased among those who received MSC (MD = 3.38 (1.89; 4.87), p < 0.001). LVESV (MD = -9.14 (-13.25; -5.03), p < 0.001), LVEDV (MD = -8.34 -13.41; -3.27), p < 0.001), and scar size (standardized MD = -0.32 (-0.60; -0.05), p = 0.02) were significantly decreased. NYHA class (MD = -0.19 (-0.34; -0.06), p = 0.006), BNP level (standardized MD = -0.28 (-0.50; -0.06), p = 0.01), and MLHFQ (MD = -11.55 (-16.77; -6.33), p = 0.005) significantly decreased and 6-min walk test significantly improved (MD = 36.86 (11.22; 62.50), p = 0.001) in the MSC group. Trials were not affected by the participants' etiology of heart failure, while trials with the autologous source of cells, MSC doses lower than 100 million cells, and intracoronary injection performed significantly better in some of the outcomes. Transplantation of MSCs for ischemic or dilated heart failure patients may reduce all-cause mortality and improve clinical condition. Moreover, this treatment would improve left ventricular function indices and reduce scar size.
Sections du résumé
BACKGROUND
BACKGROUND
The effects of mesenchymal stem cells (MSCs) on heart failure (HF) have been controversial. This study was conducted to investigate whether the transplantation of MSCs after HF could help improve clinical outcomes and myocardial performance indices.
METHODS
METHODS
Using a systematic approach, electronic databases were searched for randomized controlled trials (RCTs), which evaluated the transplantation of MSCs after HF. The outcomes owf interest included clinical outcomes and myocardial function indices. We also assessed the role of age, cause of heart failure, cell origin, cell number, type of donor (autologous/allogeneic), and route of cell delivery on these outcomes. Using the random-effects method, a relative risk (RR) or mean difference (MD) and their corresponding 95% confidence intervals (CI) were pooled.
RESULTS
RESULTS
Seventeen RCTs including 1684 patients (927 and 757 patients in the intervention and control arms, respectively) were enrolled. The RR (95% CI) of mortality was 0.78 (0.62; 0.99, p = 0.04) in the MSC group compared to the controls. HF rehospitalization decreased in the MSC group (RR = 0.85 (0.71-1.01), p = 0.06), but this was only significant in those who received autologous MSCs (RR = 0.67 (0.49; 0.90), p = 0.008). LVEF was significantly increased among those who received MSC (MD = 3.38 (1.89; 4.87), p < 0.001). LVESV (MD = -9.14 (-13.25; -5.03), p < 0.001), LVEDV (MD = -8.34 -13.41; -3.27), p < 0.001), and scar size (standardized MD = -0.32 (-0.60; -0.05), p = 0.02) were significantly decreased. NYHA class (MD = -0.19 (-0.34; -0.06), p = 0.006), BNP level (standardized MD = -0.28 (-0.50; -0.06), p = 0.01), and MLHFQ (MD = -11.55 (-16.77; -6.33), p = 0.005) significantly decreased and 6-min walk test significantly improved (MD = 36.86 (11.22; 62.50), p = 0.001) in the MSC group. Trials were not affected by the participants' etiology of heart failure, while trials with the autologous source of cells, MSC doses lower than 100 million cells, and intracoronary injection performed significantly better in some of the outcomes.
CONCLUSION
CONCLUSIONS
Transplantation of MSCs for ischemic or dilated heart failure patients may reduce all-cause mortality and improve clinical condition. Moreover, this treatment would improve left ventricular function indices and reduce scar size.
Identifiants
pubmed: 39174960
doi: 10.1186/s12967-024-05352-y
pii: 10.1186/s12967-024-05352-y
doi:
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
786Informations de copyright
© 2024. The Author(s).
Références
Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D’Agostino RB, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation. 2008;118(20):2057–62.
pubmed: 18955667
pmcid: 2729712
doi: 10.1161/CIRCULATIONAHA.108.784215
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–87.
pubmed: 35150240
doi: 10.1093/cvr/cvac013
Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171(3):368–76.
pubmed: 24398230
doi: 10.1016/j.ijcard.2013.12.028
Heidenreich Paul A, Bozkurt B, Aguilar D, Allen Larry A, Byun Joni J, Colvin Monica M, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263–421.
pubmed: 35379503
doi: 10.1016/j.jacc.2021.12.012
Attar A, Bahmanzadegan Jahromi F, Kavousi S, Monabati A, Kazemi A. Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials. Stem Cell Res Ther. 2021;12(1):600.
pubmed: 34876213
pmcid: 8650261
doi: 10.1186/s13287-021-02667-1
Fisher SA, Doree C, Mathur A, Martin-Rendon E. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res. 2015;116(8):1361–77.
pubmed: 25632038
doi: 10.1161/CIRCRESAHA.116.304386
Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011;109(8):923–40.
pubmed: 21960725
pmcid: 3604746
doi: 10.1161/CIRCRESAHA.111.243147
Menasché P, Hagège AA, Scorsin M, Pouzet B, Desnos M, Duboc D, et al. Myoblast transplantation for heart failure. Lancet. 2001;357(9252):279–80.
pubmed: 11214133
doi: 10.1016/S0140-6736(00)03617-5
Nigro P, Bassetti B, Cavallotti L, Catto V, Carbucicchio C, Pompilio G. Cell therapy for heart disease after 15 years: unmet expectations. Pharmacol Res. 2018;127:77–91.
pubmed: 28235633
doi: 10.1016/j.phrs.2017.02.015
Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311(1):62–73.
pubmed: 24247587
pmcid: 4111133
doi: 10.1001/jama.2013.282909
Hosseinpour A, Kheshti F, Kazemi A, Attar A. Comparing the effect of bone marrow mononuclear cells with mesenchymal stem cells after acute myocardial infarction on improvement of left ventricular function: a meta-analysis of clinical trials. Stem Cell Res Ther. 2022;13(1):203.
pubmed: 35578329
pmcid: 9109324
doi: 10.1186/s13287-022-02883-3
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International society for cellular therapy position statement. Cytotherapy. 2006;8(4):315–7.
pubmed: 16923606
doi: 10.1080/14653240600855905
Allickson JG, Sanchez A, Yefimenko NF, Borlongan CV, Sanberg PR. Recent studies assessing the proliferative capability of a novel adult stem cell identified in menstrual blood. Open Stem Cell J. 2011;2011(3):4–10.
doi: 10.2174/1876893801103010004
Karantalis V, Schulman IH, Balkan W, Hare JM. Allogeneic cell therapy: a new paradigm in therapeutics. Circ Res. 2015;116(1):12–5.
pubmed: 25552688
pmcid: 4411634
doi: 10.1161/CIRCRESAHA.114.305495
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
pubmed: 33782057
pmcid: 8005924
doi: 10.1136/bmj.n71
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range, and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
pubmed: 25524443
pmcid: 4383202
doi: 10.1186/1471-2288-14-135
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
pubmed: 31462531
doi: 10.1136/bmj.l4898
McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2020. https://doi.org/10.1002/jrsm.1411 .
doi: 10.1002/jrsm.1411
pubmed: 32336025
Perin EC, Borow KM, Silva GV, DeMaria AN, Marroquin OC, Huang PP, et al. A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ Res. 2015;117(6):576–84.
pubmed: 26148930
doi: 10.1161/CIRCRESAHA.115.306332
Mohy ABM, Nikbin B, Mohamad HM, Sanatkar M, Gasemi M, Mirkhani H, et al. Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. 2007.
Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61(23):2329–38.
pubmed: 23583246
doi: 10.1016/j.jacc.2013.02.071
Mathiasen AB, Qayyum AA, Jørgensen E, Helqvist S, Fischer-Nielsen A, Kofoed KF, et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). Eur Heart J. 2015;36(27):1744–53.
pubmed: 25926562
doi: 10.1093/eurheartj/ehv136
Zhao X, Xu Y, Zhu Z, Gao C, Shi Y. Clinical observation of umbilical cord mesenchymal stem cell treatment of severe systolic heart failure. Genet Mol Res. 2015;14(2):3010–7.
pubmed: 25966065
doi: 10.4238/2015.April.10.11
Bartolucci J, Verdugo FJ, González PL, Larrea RE, Abarzua E, Goset C, et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial [randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). Circ Res. 2017;121(10):1192–204.
pubmed: 28974553
pmcid: 6372053
doi: 10.1161/CIRCRESAHA.117.310712
Bartunek J, Terzic A, Davison BA, Filippatos GS, Radovanovic S, Beleslin B, et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J. 2017;38(9):648–60.
pubmed: 28025189
Xiao W, Guo S, Gao C, Dai G, Gao Y, Li M, et al. A randomized comparative study on the efficacy of intracoronary infusion of autologous bone marrow mononuclear cells and mesenchymal stem cells in patients with dilated cardiomyopathy. Int Heart J. 2017;58(2):238–44.
pubmed: 28190794
doi: 10.1536/ihj.16-328
Qayyum AA, Mathiasen AB, Mygind ND, Vejlstrup NG, Kastrup J. Cardiac magnetic resonance imaging used for evaluation of adipose-derived stromal cell therapy in patients with chronic ischemic heart disease. Cell Transplant. 2019;28(12):1700–8.
pubmed: 31698917
pmcid: 6923551
doi: 10.1177/0963689719883592
Yau TM, Pagani FD, Mancini DM, Chang HL, Lala A, Woo YJ, et al. Intramyocardial injection of mesenchymal precursor cells and successful temporary weaning from left ventricular assist device support in patients with advanced heart failure: a randomized clinical trial. JAMA. 2019;321(12):1176–86.
pubmed: 30912838
pmcid: 6439694
doi: 10.1001/jama.2019.2341
Bolli R, Perin EC, Willerson JT, Yang PC, Traverse JH, Henry TD, et al. Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients: the CCTRN SENECA trial. Cardio Oncol. 2020;2(4):581–95.
Ulus AT, Mungan C, Kurtoglu M, Celikkan FT, Akyol M, Sucu M, et al. Intramyocardial transplantation of umbilical cord mesenchymal stromal cells in chronic ischemic cardiomyopathy: a controlled, randomized clinical trial (HUC-HEART Trial). Int J Stem Cells. 2020;13(3):364–76.
pubmed: 32840230
pmcid: 7691850
doi: 10.15283/ijsc20075
Bolli R, Mitrani RD, Hare JM, Pepine CJ, Perin EC, Willerson JT, et al. A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. Eur J Heart Fail. 2021;23(4):661–74.
pubmed: 33811444
doi: 10.1002/ejhf.2178
Qayyum AA, Mouridsen M, Nilsson B, Gustafsson I, Schou M, Nielsen OW, et al. Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure. ESC Heart Fail. 2023. https://doi.org/10.1002/ehf2.14281 .
doi: 10.1002/ehf2.14281
pubmed: 36638837
pmcid: 10053281
Qayyum AA, van Klarenbosch B, Frljak S, Cerar A, Poglajen G, Traxler-Weidenauer D, et al. Effect of allogeneic adipose tissue derived mesenchymal stromal cell treatment in chronic ischemic heart failure with reduced ejection fraction - The SCIENCE Trial. Eur J Heart Fail. 2023. https://doi.org/10.1002/ejhf.2772 .
doi: 10.1002/ejhf.2772
pubmed: 36644821
Perin Emerson C, Borow Kenneth M, Henry Timothy D, Mendelsohn Farrell O, Miller Leslie W, Swiggum E, et al. Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure. J Am Coll Cardiol. 2023;81(9):849–63.
pubmed: 36858705
doi: 10.1016/j.jacc.2022.11.061
Kalou Y, Al-Khani AM, Haider KH. Bone marrow mesenchymal stem cells for heart failure treatment: a systematic review and meta-analysis. Heart Lung Circ. 2023;32(7):870–80.
pubmed: 36872163
doi: 10.1016/j.hlc.2023.01.012
Krishna Mohan GV, Tirumandyam G, Vemulapalli HS, Vajje J, Asif H, Saleem F. Mesenchymal stem cell therapy for a better prognosis of heart failure: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2023;15(8):e43037.
pubmed: 37674948
pmcid: 10479956
Shen T, Xia L, Dong W, Wang J, Su F, Niu S, et al. A systematic review and meta-analysis: safety and efficacy of mesenchymal stem cells therapy for heart failure. Curr Stem Cell Res Ther. 2021;16(3):354–65.
pubmed: 32867655
doi: 10.2174/1574888X15999200820171432
Fan M, Huang Y, Chen Z, Xia Y, Chen A, Lu D, et al. Efficacy of mesenchymal stem cell therapy in systolic heart failure: a systematic review and meta-analysis. Stem Cell Res Ther. 2019;10(1):150.
pubmed: 31151406
pmcid: 6544951
doi: 10.1186/s13287-019-1258-1
Fu H, Chen Q. Mesenchymal stem cell therapy for heart failure: a meta-analysis. Herz. 2020;45(6):557–63.
pubmed: 30341444
doi: 10.1007/s00059-018-4762-7
Qiu G, Zheng G, Ge M, Wang J, Huang R, Shu Q, Xu J. Functional proteins of mesenchymal stem cell-derived extracellular vesicles. Stem Cell Res Ther. 2019;10(1):359.
pubmed: 31779700
pmcid: 6883709
doi: 10.1186/s13287-019-1484-6
Wang J, Xia J, Huang R, Hu Y, Fan J, Shu Q, Xu J. Mesenchymal stem cell-derived extracellular vesicles alter disease outcomes via endorsement of macrophage polarization. Stem Cell Res Ther. 2020;11(1):424.
pubmed: 32993783
pmcid: 7522905
doi: 10.1186/s13287-020-01937-8
Lorkeers SJJO, Eding JE, Vesterinen HM, van der Spoel TI, Sena ES, Duckers HJ, et al. Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies. Circ Res. 2015;116(1):80–6.
doi: 10.1161/CIRCRESAHA.116.304872
Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369–79.
pubmed: 23117550
pmcid: 4762261
doi: 10.1001/jama.2012.25321
Schmelzer E, McKeel DT, Gerlach JC. Characterization of human mesenchymal stem cells from different tissues and their membrane encasement for prospective transplantation therapies. BioMed Res Int. 2019. https://doi.org/10.1155/2019/6376271 .
doi: 10.1155/2019/6376271
pubmed: 30941369
pmcid: 6421008
Gan L, Liu Y, Cui D, Pan Y, Zheng L, Wan M. Dental tissue-derived human mesenchymal stem cells and their potential in therapeutic application. Stem Cells Int. 2020. https://doi.org/10.1155/2020/8864572 .
doi: 10.1155/2020/8864572
pubmed: 33149742
pmcid: 7603635
Nowzari F, Zare M, Tanideh N, Meimandi-Parizi A, Kavousi S, Saneian SM, et al. Comparing the healing properties of intra-articular injection of human dental pulp stem cells and cell-free-secretome on induced knee osteoarthritis in male rats. Tissue Cell. 2023;82:102055.
pubmed: 36948080
doi: 10.1016/j.tice.2023.102055
Pieper IL, Smith R, Bishop JC, Aldalati O, Chase AJ, Morgan GJ, Thornton CA. Isolation of mesenchymal stromal cells from peripheral blood of ST elevation myocardial infarction patients. Artif Organs. 2017;41:654–66.
pubmed: 28245527
doi: 10.1111/aor.12829